Careers
Media
Investors
Contact us
Company
Company
Purpose
Strategy
Leadership
History
Locations
Offering
Offering
Drug Substances
Exclusive synthesis
API portfolio
Viral vectors
Drug Products
Oral solids
Steriles
Ophthalmics
Inhalation products
Technologies
Sustainability
Sustainability
People
Environment
Integrity
Quality
Community engagement
Risk management
Insights
Company
Purpose
Strategy
Leadership
History
Locations
Offering
Drug Substances
Exclusive synthesis
API portfolio
Viral vectors
Drug Products
Oral solids
Steriles
Ophthalmics
Inhalation products
Technologies
Sustainability
People
Environment
Integrity
Quality
Community engagement
Risk management
Insights
Careers
Media
Investors
Contact us
What are you
looking for?
Search
Home
/
Our expert insights
/
Overcoming challenges in transferring a sterile biologics drug product to a CDMO
Back to overview
Olaf Wegener
Head of Research & Development, Siegfried Hameln
Webinar
Oct 30, 2023
Overcoming challenges in transferring a sterile biologics drug product to a CDMO
Webinar
This presentation was originally given at CPHI 2023 in Barcelona.
Watch the webinar
To top
